Costa Rica: A recent systematic review published in the Cureus Journal of Medical Science has shed light on the potential of ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

More data, this time from a large observational study, are bolstering the idea that glucagon-like peptide-1 (GLP-1) receptor agonists offer neuroprotective and cerebrovascular benefits beyond what can ...

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little evidence of improving cardiorespiratory fitness, researchers say.

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Thrive Health Solutions also faces a lawsuit from drugmaker Eli Lilly, for allegedly making false claims about FDA approval ...